GlobalData has completed its acquisition of intelligence solutions provider for the global life sciences sector, Deallus, for an undisclosed amount.

The data, analytics and insights platform said the deal further progresses its M&A strategy.

In its two decades in business, London-based Deallus has supported clients in key therapy areas, including oncology, neuroscience, vaccines, rare diseases, cell and gene and immunology.

GlobalData said that the combination creates the opportunity for it to “build deeper, more embedded relationships with major brands in the pharmaceutical sector”, while creating potential for it "deliver more value" for its clients.

The deal was funded by GlobalData’s recently announced debt facilities and was completed on 31 December 2024.

It was the fourth acquisition completed by the group in the second half of 2024, which included the respective takeovers of Business Trade Media International, LinkUp and Celent.

Chief executive officer at GlobalData, Mike Danson, said: "This acquisition further enhances our capabilities in delivering life sciences solutions, allowing us to deliver even more comprehensive insights and services to our clients.

"Deallus's deep sector expertise and client-first mindset perfectly align with our mission to empower decision-makers in navigating the complexities of the healthcare landscape. Together, we are poised to drive remarkable growth and deliver exceptional value to our stakeholders."

---